澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

ACDC Metals Ltd

0.056

-0.001-1.75%

成交量：5.06萬

成交額：2,788.00

市值：419.61萬

市盈率：-5.94

高：0.057

開：0.057

低：0.055

收：0.057

52周最高：0.160

52周最低：0.036

股本：7,493.08萬

流通股本：4,028.75萬

量比：0.82

換手率：0.13%

股息：- -

股息率：- -

每股收益(TTM):-0.009

每股收益(LYR):-0.009

淨資產收益率：-6.71%

總資產收益率：-2.92%

市淨率：0.41

市盈率(LYR):-5.94

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO

先聲藥業(02096.HK)：SIM0609(CDH17抗體偶聯藥物)獲國家藥品監督管理局簽發藥物臨床試驗批准通知書

招銀國際：首次覆蓋維立志博-B(09887.HK)予「買入」評級目標價63.5港元

阿斯利康第二款ADC藥物在國內獲批用於乳腺癌

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hant/stock/ADC.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ADC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ADC.AU\",,,,,undefined,":{"symbol":"ADC.AU","market":"AU","secType":"STK","nameCN":"ACDC Metals Ltd","latestPrice":0.056,"timestamp":1771823520000,"preClose":0.057,"halted":0,"volume":50600,"delay":0,"changeRate":-0.017543859649122823,"nameEN":"ACDC Metals Ltd","floatShares":40287509,"shares":74930755,"eps":-0.00943,"marketStatus":"已收盤","change":-0.001,"latestTime":"02-23 16:12:00 AEDT","open":0.057,"high":0.057,"low":0.055,"amount":2788,"amplitude":0.035088,"askPrice":0.056,"askSize":1013,"bidPrice":0.052,"bidSize":200000,"shortable":3,"etf":0,"ttmEps":-0.00943,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1771887600000},"marketStatusCode":5,"adr":0,"listingDate":1673787600000,"exchange":"ASX","adjPreClose":0.057,"openAndCloseTimeList":[[1771801200000,1771822800000]],"volumeRatio":0.818696,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ADC.AU\",,,,,undefined,":{"symbol":"ADC.AU","floatShares":40287509,"roa":"-2.92%","roe":"-6.71%","lyrEps":-0.00943,"volumeRatio":0.818696,"shares":74930755,"dividePrice":0,"high":0.057,"amplitude":0.035088,"preClose":0.057,"low":0.055,"week52Low":0.036,"pbRate":"0.41","psRate":"12.18","week52High":0.16,"institutionHeld":0,"latestPrice":0.056,"committee":0.989921,"eps":-0.00943,"divideRate":0,"volume":50600,"delay":0,"ttmEps":-0.00943,"open":0.057,"prevYearClose":0.065,"prevWeekClose":0.057,"prevMonthClose":0.049,"prevQuarterClose":0.065,"fiveDayClose":0.058,"twentyDayClose":0.06,"sixtyDayClose":0.06},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADC.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2576048378","title":"Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO","url":"https://stock-news.laohu8.com/highlight/detail?id=2576048378","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576048378?lang=zh_tw&edition=fundamental","pubTime":"2025-10-18 22:46","pubTimestamp":1760798760,"startTime":"0","endTime":"0","summary":"CHENGDU, China, Oct. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.  announced that at the 2025 European Society for Medical Oncology  Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Breast02 study of the Company's trophoblast cell-surface antigen 2 -directed antibody-drug conjugate sacituzumab tirumotecan (佳泰莱) in previously treated locally advanced or metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 -negative  breast cancer  was presented as an oral report by Professor Man Li from the Second Affiliated Hospital of Dalian Medical University . Previously, the new indication applications for sac-TMT for this indication was accepted by the National Medical Products Administration  and was included in the priority review and approval process.","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2799758/image_1.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2799758/image_1.jpg?w=300"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/kelun-biotech-presents-positive-results-of-phase-3-clinical-study-optitrop-breast02-for-sacituzumab-tirumotecan-in-advanced-hrher2--breast-cancer-at-2025-esmo-302588212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","BK4231","BC","BK4203","ADC.AU","BK7095","HR","BK4190","ADC","BK4225"],"gpt_icon":0},{"id":"2565899846","title":"先聲藥業(02096.HK)：SIM0609(CDH17抗體偶聯藥物)獲國家藥品監督管理局簽發藥物臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2565899846","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565899846?lang=zh_tw&edition=fundamental","pubTime":"2025-09-08 20:12","pubTimestamp":1757333548,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ADC","02096","BK4080","BK1191","BK1583","BK7095","BK4231","ADC.AU"],"gpt_icon":0},{"id":"2564325557","title":"招銀國際：首次覆蓋維立志博-B(09887.HK)予「買入」評級 目標價63.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2564325557","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564325557?lang=zh_tw&edition=fundamental","pubTime":"2025-09-04 14:14","pubTimestamp":1756966477,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ADC.AU","ADC","BK4023","BK4080","09887","PD","BK7095","BK4231","BK1161","LU1169589451.USD","LU1169590202.USD"],"gpt_icon":0},{"id":"2561474908","title":"阿斯利康第二款ADC藥物在國內獲批用於乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2561474908","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561474908?lang=zh_tw&edition=fundamental","pubTime":"2025-08-22 20:38","pubTimestamp":1755866311,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4231","HR","LU0109394709.USD","LU2417539215.USD","LU2456880835.USD","BK7095","ADC.AU","LU2462157665.USD","LU0320765992.SGD","LU1829250122.USD","BK4568","BK4007","LU2236285917.USD","BK4203","BK4225","BK4585","AZN","LU0889565916.HKD","BK4080","BK4588","ADC"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ADC.AU\",params:#limit:6,delay:true,,,undefined,":[]}}